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Abstract: Age-related macular degeneration (AMD) complications are the leading cause of 
severe vision loss among the aging population in the many western countries. The introduction 
of molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, 
ranibizumab, and bevacizumab, as treatments for wet AMD has provided new hope for affected 
patients. Now we have these treatment options, which have the possibility to improve or maintain 
visual acuity for patients suffering from AMD. The treatment needs to be optimized and this is 
in progress. Based on emerging evidence, adopting a variable VEGF inhibitor-dosing strategy 
guided by visual acuity assessment and optical coherence tomography are now being tried 
to reduce the frequency of injections. VEGF inhibitors in combination with photodynamic 
therapy are another way to optimize treatment. Physicians are waiting for new guidelines for the 
  management of AMD and the results of current and upcoming trials systematically addressing 
these issues will be expected to provide it.
Keywords: age-related macular degeneration, VEGF inhibitor, verteporfin, pegaptanib, 
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Age-related macular degeneration  
and treatment options
Age-related macular degeneration (AMD) complications are the leading cause of severe 
vision loss among people aged 65 years and over in the United States1 and many western 
countries. AMD is grouped into two types, dry (nonexudative or nonneovascular) and 
wet (exudative or neovascular) macular degeneration. About 10%–20% of people with 
AMD have the wet type, but most (approximately 90%) of this vision loss is due to 
neovascular (or wet-type) AMD.2 The word ‘neovascular’ describes the development 
of new, abnormal blood vessels in the back of the eye. These new abnormal vessels 
are fragile, and often extravasate blood components, which occasionally becomes 
subretinal or vitreous bleeding resulting in sudden visual disturbance. Unfortunately, 
the majority of these new vessels were not amenable to treatment except by laser-
photocoagulation including photodynamic therapy, which selectively destroys new 
abnormal vessels with verteporfin (Visudyne®, a light-activated drug) and the use of 
a low-energy laser.
The Treatment of Age-Related Macular Degeneration with Photodynamic 
Therapy (TAP) study group revealed that verteporfin therapy for predominantly 
classic choroidal neovascularization (CNV) subfoveal lesions had benefits for visual 
acuity without severe adverse effects.3 Before the advent of this treatment, treatment 
options for subfoveal or juxtafoveal CNV , including low-dose radiation therapy, were Clinical Ophthalmology 2010:4 276
Sassa and Hata Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
limited and ineffective. In 2000, the US Food and Drug 
Administration (FDA) approved Visudyne® (new drug appli-
cation number 21–119) therapy as the first drug treatment 
for predominantly classic wet-type AMD. Guidelines for 
verteporfin therapy for choroidal neovascularization second-
ary to AMD were published in 20024 and updated in 2005.5 
These guidelines were based on trials and clinical experience 
in predominantly Caucasian populations. The prevalence of 
AMD is different among racial groups. For example, the 
leading cause of blindness among white Americans was AMD 
(54.4% of cases), while among black Americans, cataract and 
glaucoma accounted for more than 60% of blindness in the 
United States.1 The leading causes of blindness in a Japanese 
adult population were glaucoma and diabetic retinopathy. 
Oxidative damage-induced inflammation initiates AMD.6 
Macular pigments, which work as antioxidants to prevent 
oxidative stress from lights, are one of the reasons for the 
differences in AMD prevalence among racial groups.7 More 
macular pigments are found in the retinas of Asians and 
blacks compared to retinas in whites. However, results from 
population-based studies show that the five-year incidence 
of AMD in Japan was close to those in western countries 
(Hisayama Study [0.8%],8 Beaver Dam Eye Study [0.9%],9 
Blue Mountain Eye Study [1.1%]10). Subsequently, the 
Japanese Age-Related Macular Degeneration Trial (JAT) was 
designed to evaluate photodynamic therapy for Japanese and 
found it to be efficacious and safe in Asian patients as well 
as in Caucasian patients.11 In 2004, verteporfin therapy was 
approved for Japanese patients with wet-type AMD.
The effectiveness of verteporfin therapy depends on 
the types of AMD in United States. Verteporfin therapy 
  maintained visual acuity for patients with predominantly 
classic CNV. However, there is insufficient evidence in 
  minimally classic CNV . In Japan, verteporfin therapy was 
able to maintain visual acuity for at least one year in patients 
with both types of CNV: predominantly classic and minimally 
classic lesions. Although this new laser therapy achieved 
some progress in the treatment for AMD, the effectiveness 
of this therapy is still limited; it maintained visual acuity, 
but did not improve it.
Vascular endothelial growth factor (VEGF) is a glycoprotein 
that stimulates the growth of new blood vessels. This broad 
term, ‘VEGF’, covers a number of proteins that result from 
alternate splicing of mRNA from a single 8-exon VEGF gene. 
Alternate splicing of exon 6 and 7 alters their amino acid 
number (in humans: VEGF121, VEGF145, VEGF165, VEGF189, 
VEGF206). Among them, VEGF121 and VEGF165 are mainly 
expressing in the eye. The results of the VEGF Inhibition 
Study in Ocular Neovascularization (VISION) clinical trials 
in late 2004 marked a new era for the treatment of AMD. This 
trial tested the concept that targeting VEGF, a potent promoter 
of angiogenesis, could affect the formation of neovascular 
vessels in AMD and it was shown to be correct.12 They used 
pegaptanib (Macugen®), a 28-base ribonucleic acid aptamer, 
which binds to the VEGF165 isoform with high specificity and 
affinity but does not bind to the other VEGF isoforms.13 This 
trial clinically proved that anti-VEGF therapy is a promising 
therapy for the patients with wet-type AMD. Ranibizumab 
(Lucentis®) is an antibody fragment that binds and inhibits 
all identified VEGF isoforms.14 Ranibizumab was approved 
by the FDA in 2006 for the treatment of advanced or wet-type 
AMD. The approval was based on evidence from clinical tri-
als showing that ranibizumab slows the rate of progression 
of vision loss from wet AMD.15 In addition to a low rate of 
developing vision loss, approximately one-third of patients 
treated in these trials had some improvement in vision at 
24 months as measured on an eye chart.15 The Anti-VEGF 
Antibody for Treatment of Predominant Classic Choroidal 
  Neovascularization in Age-Related Macular Degeneration 
(ANCHOR study group) trial revealed that ranibizumab 
was superior to verteporfin as an intravitreal treatment of 
predominantly classic CNV.16 In this study, ranibizumab 
improved visual acuity at one year on average.16 Bevacizumab 
  (AvastinTM) is a drug closely related to ranibizumab. It was 
approved by the FDA in 2004 as an intravenous treatment 
for patients with advanced colorectal cancer and therefore 
has been available for what is called off-label use for other 
health conditions. It has been widely used to treat wet-type 
AMD. Bevacizumab is thought to remain in the eye longer 
than ranibizumab and therefore possibly allows for less fre-
quent injections. No formal dose-ranging or dosing frequency 
  studies have been performed. Almost all of the evidence comes 
from off-label usage in short-term uncontrolled clinical case 
series, but the results suggest that is associated with vision 
stabilization or improvement in most treated eyes.17–20
Anti-VEGF therapies were accepted for the treatment of 
AMD. The first anti-VEGF therapy, pegaptanib, was approved 
in Europe in 2006 and in Japan in 2008, respectively. This 
approval was shortly followed by the approval of ranibizumab 
for the treatment of neovascular AMD in Europe in 2007 and 
in Japan in 2009, respectively. The outcomes of these new 
treatments in these countries are forthcoming.
Pegaptanib (Macugen®)
Pegaptanib (50 kDa) is a specific nucleic acid ligand 
(aptamer) binding to VEGF165, which plays a critical role in Clinical Ophthalmology 2010:4 277
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angiogenesis and increased permeability. Pegaptanib was 
licensed in Japan in 2008 for the treatment of neovascular 
AMD and is administered by intravitreal injection every six 
weeks for at least two years.21
As previously described, the results of the VISION clinical 
trials in late 2004 marked a new era for the treatment of AMD. 
These clinical trials revealed the safety and efficacy of pegap-
tanib for the treatment of neovascular AMD in 1190 patients 
over two years.12,22,23 At baseline, patients were randomized to 
one of four treatment groups (0.3 mg, 1 mg, or 3 mg pegap-
tanib, or sham), with treatment administered every six weeks 
for 54 weeks (a total of nine treatments). All three doses of 
pegaptanib were effective in preventing loss of vision com-
pared with sham injections across all CNV subtypes;12 70%, 
71%, and 65% of patients receiving 0.3 mg, 1 mg, and 3 mg 
pegaptanib, respectively, experienced a loss of fewer than 
15 letters of visual acuity at week 54 compared with 55% of 
patients receiving sham injections (P  0.001, P  0.001, and 
P = 0.03, respectively compared to sham injection). In addi-
tion, 33%, 37%, and 31% of patients receiving 0.3 mg, 1 mg, 
and 3 mg pegaptanib, respectively, maintained their vision or 
gained vision compared with 23% of patients receiving sham 
injections (P = 0.003, P  0.001, and P = 0.02, respectively). 
After one year of treatment, the sham group was randomized 
to continuing sham injections, no treatment, or one of the three 
pegaptanib doses and a follow-up protocol was continued in 
the next year. As a result, mean visual acuity was maintained 
in patients receiving 0.3 mg pegaptanib and the proportion 
of patients losing fewer than 15 letters of visual acuity from 
week 54 to week 102 (7%) was half that of those who were 
assigned to two years of sham injections or randomized to 
stop treatment after one year (14%).22
Complications of intravitreal 
pegaptanib injection
The rate of complications in the eye was as follows: 
  endophthalmitis (1.3%), traumatic injury to the lens (0.7%), 
and retinal detachment (0.6%) in the first year and no reports 
of endophthalmitis or traumatic injury to the lens in the 
following year.23 There was no evidence of an increase in 
adverse effects associated with systemic VEGF inhibition 
such as hypertension, thromboembolic events, or serious 
hemorrhagic events.23 An additional one-year systemic safety 
study confirmed that there was no evidence of systemic 
VEGF inhibition even at doses up to tenfold the approved 
0.3 mg.24
The VISION clinical trials proved that anti-VEGF therapy 
is a promising therapy for the patients with wet type AMD, but 
the outcomes of the next anti-VEGF therapy; ie, ranibizumab, 
overcame those of pegaptanib therapy in terms of preventing 
visual loss of the patients with neovascular AMD. Pegaptanib 
selectively inhibits VEGF165 and never inhibits VEGF121, 
while ranibizumab inhibits all identified VEGF isoforms. 
That is one of the reasons why the ranibizumab therapy is 
more effective than pegaptanib in preventing loss of vision. 
In contrast, that reason works well for pegaptanib in terms of 
the adverse effects. In theory, this selective inhibition reduced 
the risk of both focal and systemic adverse effects because 
VEGF also works as a survival signal for cells, including 
endothelial cells and neural cells.25 In addition, pegaptanib 
is not an antibody and it is poorly immunogenic. Pegaptanib 
therapy is expected to be used as long-term maintenance 
therapy after an initial nonselective anti-VEGF therapy 
including ranibizumab or bevacizumab.
Ranibizumab (Lucentis®)
Ranibizumab is a humanized monoclonal antibody Fab 
  fragment that inhibits all human isoforms of VEGF-A, and 
was specifically designed for the treatment of neovascular 
AMD. Since it is much smaller than the parent molecule, it 
has the advantage of penetrating to deeper tissues, ie, it is 
effective in CNV beneath retinal pigment epithelial cells. 
In 2009, ranibizumab was licensed for the treatment of 
  neovascular AMD in Japan and is administered by intravitreal 
injection every four weeks for three months as an initial 
  treatment. The intervals (at least four weeks) after initial 
treatment are decided according to its effectiveness.26
The Minimally Classic/Occult Trial of the Anti-VEGF 
Antibody to Ranibizumab in the Treatment of Neovascular 
Age-Related Macular Degeneration (MARINA) study 
  investigated ranibizumab for the treatment of minimally 
classic or occult with no classic CNV associated with 
AMD at 96 sites in the United States.15 A total of 716 
patients were randomized equally to receive 24 monthly 
intravitreal injections of 0.3 or 0.5 mg ranibizumab, or 
sham injections. At 24 months, 90% of patients treated 
with 0.3 mg ranibizumab and 92% of those treated with 
0.5 mg ranibizumab lost fewer than 15 letters from baseline 
visual acuity, compared with 52.9% in the sham-injection 
group (P  0.001 for the comparison of each dose with 
the sham-injection group). Furthermore, at both 12 and 
24 months, approximately one-quarter of patients receiv-
ing 0.3 mg ranibizumab and one-third of patients receiving 
0.5 mg ranibizumab had gained 15 or more letters in visual 
acuity, compared with 5.0% in the sham-injection group at 
12 months and 3.8% at 24 months. Only 0.8% of patients Clinical Ophthalmology 2010:4 278
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receiving 0.3 mg ranibizumab and 1.2% of patients receiving 
0.5 mg ranibizumab had severe vision loss (lost 30 letters or 
more of visual acuity), compared with 14.3% of patients in 
the sham-injection group.
The ANCHOR group compared ranibizumab with 
  verteporfin photodynamic therapy for the treatment of pre-
dominantly classic neovascular AMD.16 A total of 423 patients 
were randomized equally to receive 12 monthly intravitreal 
injections of 0.3 or 0.5 mg ranibizumab plus sham verteporfin 
therapy, or monthly sham injections plus active verteporfin 
therapy. At 12 months, 94.3% of patients treated with 0.3 mg 
ranibizumab and 96.4% of those treated with 0.5 mg ranibi-
zumab lost fewer than 15 letters from baseline visual acuity 
compared with 64.3% in the sham-injection group (P  0.001 
for each comparison). Visual acuity improved by at least 15 
letters in 35.7% and 40.3% of patients in the 0.3 mg ranibi-
zumab and 0.5 mg ranibizumab treatment groups, respectively, 
compared with 5.6% of patients in the verteporfin treatment 
group (P  0.001 for each comparison).
According to recent large-scale, randomized clinical trials 
such as MARINA and ANCHOR, the standard regimen of 
ranibizumab for neovascular AMD is monthly treatments 
administered for two years.15,16 The next trial is to evaluate 
whether a regimen can be identified that may allow less 
  frequent treatments or visits without compromising visual 
acuity outcomes. The PIER study (Phase 3b, Multicenter, 
Randomized, Double-masked, Sham Injection-Controlled 
Study of the Efficacy and Safety of Ranibizumab in Subjects 
with Subfoveal Choroidal Neovascularization with or 
without CNV Secondary to AMD) evaluated ranibizumab 
  administered monthly for three months, followed by 
  injections every four months.27 A total of 184 patients were 
randomized equally to receive three monthly intravitreal 
injections of 0.3 or 0.5 mg ranibizumab, or sham injections, 
followed by injections every four months. At 12 months, 
83.3% of patients treated with 0.3 mg ranibizumab and 
90.2% of those treated with 0.5 mg ranibizumab lost fewer 
than 15 letters from baseline visual acuity, compared with 
49.2% in the sham-injection group (P  0.001 for the 
comparison of each dose with the sham-injection group). 
However, the improvement in mean visual acuity through 
month 3 was not sustained to month 12. The proportion of 
subjects with substantial improvement by at least 15 letters 
was not superior to sham treatment. Therefore, more frequent 
monitoring and dosing may be necessary to identify when 
treatment is needed.
To address this question, several studies including 
PRONT28 study and SUSTAIN29 study were performed to 
decide whether retreatment is necessary or not by either loss 
of visual acuity or the retinal thickness evaluated by optical 
coherence tomography (OCT). Even though PRONT study 
is very small (n = 40) and nonrandomized single – center 
clinical study, this trial showed the usefulness of OCT to 
reduce the frequency of injections. A second phase IIIb study 
(SUSTAIN29) is evaluated the efficacy of 0.3 mg ranibizumab 
administered monthly for three consecutive months (loading 
phase), followed by flexible dosing injection. After receiving 
three consecutive monthly injections of ranibizumab   
0.3 mg, patients returned for monthly follow-up and received 
  retreatment with ranibizumab 0.3 mg (or 0.5 mg after it 
became available) guided by visual acuity assessment and 
optical coherence tomography (OCT). At the 17th Congress 
of the European Society of Ophthalmology in Amsterdam, 
The Netherlands, the outcome of this study was reported as 
  follows: of 531 ranibizumab-naïve patients enrolled in the 
study, 455 patients reached the 12-month visit. The mean 
change in patient visual acuity at the end of the loading 
phase was +5.8 letters, and after 12 months, the improvement 
was +3.6 letters from baseline. At 12 months, 20.5% of 
patients received no additional dose, 16% required one or 
two treatments, and 13% required three or four injections 
after the loading phase. Although patients still require 
monthly follow-up, this study suggested the possibility of 
less frequent treatments to sustain visual acuity acquired 
after the loading phase.
Complications of intravitreal 
ranibizumab injection
MARINA study
The rate of complications in the eye for endophthalmitis 
was 1.0% (5 of 477 patients) 0.05% (5 of 10,443 injections) 
in the ranibizumab injection group with none in the sham-
injection group. The rate of complications for serious uveitis 
was 1.3% (6 of 477 patients) in the ranibizumab injection 
group with none in the sham-injection group. There was no 
significant difference between the three treatment groups in 
the rates of systemic complications. The rates of hypertension 
(17.2%, 16.3%, and 16.1% in the 0.3 mg ranibizumab, 0.5 mg 
ranibizumab, and sham-injection groups, respectively) 
and arterial thrombolic events (4.6%, 4.6%, and 3.8% in 
the 0.3 mg ranibizumab, 0.5 mg ranibizumab, and sham-
injection groups, respectively) were similar across groups at 
24 months. Nonocular hemorrhage rates were 9.2%, 8.8%, 
and 5.5% in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, 
and sham-injection groups, respectively at 24 months but 
these differences were not significant.Clinical Ophthalmology 2010:4 279
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ANCHOR study
The rate of complications in the eye for endophthalmitis 
was 0.7% (2 of 277 patients) in ranibizumab injection group 
with none in the verteporfin injection group. The rate of 
  complications for serious uveitis was 0.4% in the ranibi-
zumab injection group with none in the verteporfin injection 
group. Interestingly, immunoreactivity to ranibizumab 
increased in the patients treated with 0.5 mg ranibizumab. 
Patients with immunoreactivity had more adverse events 
associated with intraocular inflammation than those without 
immunoreactivity at any point although the rate of patients 
with immunoreactivity is small at 12 months (1.6%, 3.9%, 
and 1.6% in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, 
and verteporfin injection groups, respectively). Transient 
changes in intraocular pressure after injection were com-
mon in the ranibizumab injection group. Intraocular pres-
sure over 30 mmHg after injection was more obvious in the 
ranibizumab injection group at 12 months (8.8%, 8.6%, 
and 4.2% in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, 
and verteporfin injection groups, respectively). There was 
no significant difference in the rates of arterial thrombolic 
events between the three treatment groups.
SAILOR study
An interim safety analysis from the Safety Assessment of 
Intravitreal Lucentis for AMD (SAILOR) trial indicated 
a higher incidence of strokes in the 0.5 mg dose group 
  compared with the 0.3 mg dose group30 (1.2% versus 0.3%, 
respectively; P = 0.02). Patients with a history of prior stroke 
appeared to be at higher risk for a subsequent stroke.
Bevacizumab (AvastinTM)
Since bevacizumab was available prior to the launch of ranibi-
zumab, bevacizumab is the most commonly used medication 
in the eye. This molecule has two antigen-binding domains 
(ranibizumab has one). Only a limited number of studies of 
bevacizumab have evaluated acute retinal toxicity in animals, 
and no toxicity has been identified. No formal dose-ranging or 
dosing-frequency studies have been performed. Bevacizumab 
is associated with vision stabilization or improvement in most 
treated eyes and simultaneous improvements in OCT and 
fluorescein angiographic markers of disease activity.17–20
In Europe, bevacizumab is currently approved for the 
treatment of colorectal cancer and advanced or metastatic 
renal cell cancer, and has been also used on off-label basis 
for the treatment of AMD.31,32 Several trials demonstrated that 
bevacizumab achieved a level of success for the treatment 
of AMD without severe adverse effects in Europe.31,32 In the 
United Kingdom, the National Health Service is running a 
multicenter clinical trial, IVAN (Inhibit VEGF in Age-related 
choroidal Neovascularization) study, to compare safety and 
efficacy of ranibizumab and bevacizumab for the treatment 
of neovascular AMD.
Intravitreal bevacizumab in combination 
with verteporfin photodynamic therapy
In Japan, bevacizumab has been used for eye diseases since 
2005. To the best of our knowledge, there are few reports 
about the outcomes of intravitreal bevacizumab for Asian 
patients with AMD.33–35 One report from Japan demon-
strated that combined photodynamic therapy and intravitreal 
bevacizumab injection reduced the height of retinal pigment 
epithelial detachment secondary to AMD evaluated by OCT 
and stabilized visual acuity at one year.29 In this report, two 
eyes in 22 cases (9%) had decreased vision due to a retinal 
pigment epithelial tear and subretinal hemorrhage.
Complications of intravitreal  
bevacizumab injection
In Japan, Iizima and colleagues surveyed the use of beva-
cizumab in 106 hospitals, where verteporfin therapy was 
administered to AMD patients.36 Although this article was 
published in Japanese, the survey of the use and safety of 
intravitreal bevacizumab injections in Asian patients is 
valuable. In this article, bevacizumab was used for diseases 
such as AMD, polypoidal choroidal vasculopathy, retinal 
angiomatous proliferation, myopic choroidal neovascular 
vessels, CNV in angioid streaks, macular edema in nonisch-
emic branch/central retinal vein occlusion, and diabetic 
maculopathy. Bevacizumab was used at the dose of 1.25 
mg/0.05 mL for single injection in almost all hospitals (93%). 
There were 21,328 injections in total in this trial. The rate 
of complications in the eye was as follows: endophthalmitis 
(0.04%), retinal detachment (0.03%), retinal hemorrhages 
after injection (0.06%), traumatic injury to the lens (0.06%), 
retinal pigment epithelial tears (0.15%), uveitis (0.03%), 
elevated intraocular pressure (0.01%), retinal breaks (0.02%), 
and acute visual loss without apparent reasons (0.05%). Reti-
nal artery occlusion was observed only in one case. The rate 
of systemic complications was as follows: cerebral infarc-
tion (0.06%), menstrual irregularity (0.05%), and cutaneous 
change (0.02%). Elevated blood pressure was observed in 
only one case.
Fung and colleagues reported complications in patients 
after intravitreal bevacizumab injection.37 In this trial, 
there were 7,113 injections in total that were complicated Clinical Ophthalmology 2010:4 280
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by endophthalmitis (0.01%), retinal detachment (0.04%), 
  traumatic injury to the lens (0.01%), retinal pigment epi-
thelial tears (0.06%), subretinal bleeding (0.06%), uveitis 
(0.14%), elevated intraocular pressure (0.01%), retinal artery 
  occlusion (0.01%), and acute visual loss without apparent 
reason (0.07%). Systemic complications were cerebral infarc-
tion (0.07%) and elevated blood pressure (0.21%).
The rate of complications presented above appears to 
be lower than those from the MARINA or VISION clinical 
trials since the rates were calculated by the number of total 
  injections in our two trials (Iizima and Fung), while the 
rates were calculated by the number of total patients in the 
MARINA or VISION trials. Shima and colleagues reported 
the rate of complications per patient (total 707 patients) within 
two month after intravitreal injection of bevacizumab38 were 
endophthalmitis (0.28%), traumatic injury to the lens (0.14%), 
retinal pigment epithelial tears (0.14%), uveitis (0.28%), and 
acute visual loss without apparent reason (0.28%). Systemic 
complications were cerebral infarction (0.14%), menstrual 
irregularity (0.42%), cutaneous change (0.28%), and elevated 
blood pressure (0.28%).
Cerebral infarction is one of the more severe complica-
tions after intravenous injection of bevacizumab combined 
with other anticancer agents for the treatment of colorectal 
cancer. However, it is difficult to determine whether stroke 
is caused by chemotherapy or cancer itself, because some 
tumors are at high risk for cerebrovascular complications.39 
Since VEGF stimulates the synthesis of endothelial nitric 
oxide synthase and prostacyclin in endothelial cells,40–42 
anti-VEGF drugs may inhibit these properties and result in 
vascular occlusions, including cerebral infarction and retinal 
artery occlusions.
Ranibizumab vs bevacizumab: 
What’s the difference?
Ranibizumab and bevacizumab are produced by the same 
company, Genentech Inc. (San Francisco, CA), a leader 
in research and product development in the area of 
  angiogenesis. Ranibizumab (formerly known as rhuFAb V2) 
is an antibody fragment that binds and inhibits all identi-
fied VEGF isoforms, while bevacizumab is a recombinant, 
humanized, monoclonal immunoglobulin G1 antibody that 
also binds to and inhibits all isoforms of human VEGF.17,42 
In targeting VEGF, these two drugs are similar. What is 
the difference? Since ranibizumab (48.3 kDa) is an anti-
body fragment, its molecular weight is much smaller than 
bevacizumab (149 kDa). Preclinical studies suggested that 
a full-length antibody would not penetrate all layers of the 
retina (approximately 76.5 kDa).44 This is why ranibizumab 
was designed specifically to treat neovascular AMD by 
manipulating the structure of the murine monoclonal anti-
body from which bevacizumab was derived. After clinical 
evidence of a treatment effect of the full-length antibody 
(bevacizumab) in humans, additional animal studies have 
found that this particular full-length antibody can penetrate 
all retinal layers.17
The problem with ranibizumab is its cost. A single 
dose of the drug costs more than $2,000, whereas a single 
  injectable dose of bevacizumab costs about $50 in United 
States. Even the typical Medicare copayment of 20%, or 
US$400, is more than twice as costly as the full price 
of an injection of bevacizumab. In Japan, the cost of a 
single dose of ranibizumab is ¥170,000 (approximately 
US$1700), while bevacizumab is ¥1000 (approximately 
US$10). In line with the effects of the aging population 
in developed countries, the annual costs of health care 
are increasing rapidly. If bevacizumab works as an AMD 
treatment as well as ranibizumab with similar rates of 
serious adverse events, bevacizumab may be a better 
treatment for AMD. In February 2008, the National Eye 
Institute of the National Institutes of Health started a 
multicenter clinical trial to compare the relative safety 
and effectiveness of these two drugs, the Comparison of 
AMD Treatments Trials (CATT): Lucentis–Avastin Trial. 
In this trial, 1,200 patients with wet-type AMD will be 
treated with either:
1.  Injection of Lucentis on a fixed schedule of once every 
four weeks for one year. The patient is assigned randomly 
in the second year to either an injection of Lucentis every 
four weeks or on a variable schedule depending on the 
patient’s response to treatment;
2.  Injection of Avastin on a fixed schedule of once every 
four weeks for one year. The patient is assigned randomly 
in the second year to either an injection of Avastin every 
four weeks or on a variable schedule depending on the 
patient’s response to treatment;
3.  Injection of Lucentis on a variable schedule;
4.  Injection of Avastin on a variable schedule.
Evaluating points are visual acuity, number of treatments, 
anatomical changes in the retina, adverse events, and cost. 
This clinical trial is being conducted at 47 clinical centers 
in the US. It is hoped the results of this study will improve 
the treatment of wet-type AMD. Reducing the frequency of 
treatments without compromising effectiveness would reduce 
the treatment burden for patients and produce potential cost 
savings.Clinical Ophthalmology 2010:4 281
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For the same purpose as the CATT study, many studies 
including IVAN (UK), MANTA (Austria), VIBERA   
(Germany), LUCAS (Norway), GEFAL (France) and FIG-
DAME (Spain) are working in the way.
Is off-label use of drugs legal?
The FDA-labeled indication of bevacizumab is for the 
  treatment of colon cancer. Its use in the eye is therefore 
off-label; no solid data exists on its safety and efficacy. 
Is off-label use of drugs legal? Off-label use of drugs is 
not illegal. It is not uncommon to use off-label use of 
drugs including triamcinolone acetonide45 and tissue plas-
minogen activators46 for intravitreal injection. In terms of 
triamcinolone, Tano and Machemer originally reported 
that intravitreal injection of triamcinolone was effective 
to proliferative vitreoretinal diseases with an experimental 
proliferative vitreoretinopathy model.47 Several reports 
demonstrated that intravitreal injection of triamcinolone 
is effective in retinal disease such as retinal leakage48 and 
subretinal neovasculation49 in animal models. Machemer’s 
group reported that intravitreal injection of triamcinolone 
did not have retinal toxicity in rabbits with electrophysi-
ological and morphological methods.50 Fifteen years later 
in Australia, triamcinolone was intravitreally administered 
off-label.45 Fortunately, this pilot study reported that intra-
vitreal injection for exudative AMD improved visual acuity 
without severe adverse effects.45 These reports encourage 
the use of triamcinolone for vitreoretinal disease even in 
off-label use. Several clinical studies support its effective-
ness and now intravitreal injection of triamcinolone for 
vitreoretinal disease is widespread. Likewise, use of beva-
cizumab is now the most commonly used anti-VEGF drug 
in the eye. Although preclinical studies have almost exclu-
sively found bevacizumab to be safe, the design utilized 
in clinical case series cannot rule out a possible increase 
in adverse events. We should keep in mind that common 
practice does not make the use of bevacizumab safe. There 
may be a risk of unexpected adverse outcomes, but this is 
also true of labeled use of new drugs. Some adverse effects 
do not become apparent until after several years of use and 
thousands of prescriptions.
Treatment possibility for other 
diseases besides AMD
We now know VEGF-targeting pharmacotherapy works 
well for wet-type AMD, but VEGF is active in other eye 
diseases including diabetic macular edema (DME), retinal 
vascular thrombosis, neovascular glaucoma, and CNV 
resulting from other causes such as high myopia or angioid 
streaks. Several reports are now showing the effectiveness 
and safety of VEGF-targeting pharmacotherapy in these 
diseases. For retinal vascular occlusions (RVO), phase III 
trials (the CRUISE study for CRVO and the BRAVO study 
for BRVO) are now under way. The NVG study (Lucentis for 
New Onset Neovascular Glaucoma) will show us the efficacy 
and safety of lucentis treatment for neovascular glaucoma. 
DME is the second best-researched disease in treatment 
with VEGF-targeting pharmacotherapy. Two phase II trials 
(READ251 and RESOLVE) suggest a benefit for ranibizumab 
in the treatment of DME. At the 2008 Joint Meeting of the 
  American Academy of Ophthalmology and the European 
Society of Ophthalmology, the outcome of the RESOLVE 
study was reported. In this study, subjects were randomized 
to receive 3 monthly injections with either 0.3 or 0.5 mg 
ranibizumab or placebo (sham group). Treatment was then 
administered on an as-needed basis, depending on response to 
initial treatment. The dose of ranibizumab increased doubled 
after 1 month if edema resolution was incomplete. This use 
of a higher dose after 1 month was quite different from the 
way of the treatment for AMD, mainly because the VEGF 
levels in active diabetic retinopathy are higher than in AMD. 
Photocoagulation after 3 injections was given if needed. In 
this trial, ranibizumab was superior to placebo with respect 
to changes in BCVA letter score and central retinal thick-
ness. The safety profile of ranibizumab was comparable to 
that observed in patients with AMD. Phase III trials (RISE 
and RIDE) are now underway to evaluate the efficacy of 
ranibizumab in DME.
Conclusion
Although the prevalence of AMD in Japan is lower than 
those in western countries, the number of patients suffering 
from AMD is increasing as the Japanese shift from their 
traditional diet to a fatty, high calorie western diet. In the 
1990’s, treatment options for wet-type AMD were limited and 
ineffective. Now we have several treatment options, which 
have the possibility to improve or maintain visual acuity for 
patients suffering from AMD. The treatment now needs to 
be optimized and this is in progress. Several clinical trials 
are now running, including the CATT trial, combination 
therapy with photodynamic therapy, anti-VEGF drugs, and 
triamcinolone acetonide. However, even in patients with wet-
type AMD, there are patients left behind from large-scale, 
randomized clinical trials such as MARINA and ANCHOR. 
Predominantly blood or scar lesions were not included in 
those two trials. We have no treatment options available for Clinical Ophthalmology 2010:4 282
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these patients. New approaches for these types of CNV must 
be developed.
Future options
In the experimental reports, there are several new pharmaco-
therapies for AMD besides those described above. Even if we 
focus on similar mechanisms, ie, anti-VEGF drugs, several 
pharmacotherapies are now into phase III clinical trials.
Bevasiranib (Opko Health, Miami, FL) is a first-in-class 
small interfering RNA drug designed to silence the genes 
that produce VEGF. The phase III COBALT clinical trial 
will evaluate whether bevasiranib administered every eight 
or 12 weeks is as effective as ranibizumab administered 
every four weeks for preventing vision loss. Its effectiveness 
in maintenance therapy after initiation with three doses of 
ranibizumab is also under investigation.
VEGF Trap-Eye (Bayer HealthCare, Pittsburgh, PA; Regen-
eron, Tarrytown, NY) is a human soluble VEGF receptor fusion 
protein that binds all types of VEGF-A as well as the related 
placental growth factor. One arm of the phase III VIEW studies 
is enrolling a cohort to be treated with 2 mg of VEGF Trap-Eye 
every eight weeks compared with every four weeks.
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